Janssen CarePath
commercial plans
as low as $5 per infusion, up to $20,000 a year
Which program fits this patient's insurance and diagnosis, its status the last time we checked, what it pays, and how to apply.
Program terms verified · each fund's status below is dated at our last check
Pick the insurance and the diagnosis. Programs depend on both.
Used to match foundation funds.
The apply links go to the programs. Whether this patient meets the income and insurance rules, and what she would owe after the program, is the next step; CareCost works that out.
Enter your email. It opens with this insurance and diagnosis already selected. CareCost checks each program's rules against the patient's plan and diagnosis, applies the program to the estimate, and keeps the enrollment link and status with the patient's file.
Free to try. No card. No sales calls.
Eligibility rules for each program. Income limits, insurance type and diagnosis, so you call only the programs this patient can get.
The estimate with the program applied. What she owes after the fund or the card, on the drug, infusion and visit lines.
An alert when a closed fund reopens. We re-check closed and waitlisted funds and tell you when one lists as open.
No patient name is required. The estimate and the program are saved; the patient's name and chart are not. HIPAA
What it returns · follows the insurance you picked: Original Medicare, Crohn's, 80 kg example, not editable
EXAMPLE · ORIGINAL MEDICARE (PART B) · CROHN'S DISEASE (ADULT) · NOT EDITABLE
Every program on this page links to its own application page; status dates are ours. Methodology · Privacy
Foundation funds are diagnosis-based — each fund covers a specific disease state (here, ANCA-associated vasculitis, inflammatory bowel disease, rheumatoid arthritis, psoriasis or atopic dermatitis), not a specific drug, so eligibility depends on the patient's ICD-10 code, not just the prescription. Funds open and close as their donated dollars run out and refill, which is why status (open, waitlist, closed) has to be checked at the time of the patient's infusion rather than assumed from a prior visit. Funds of this type typically apply an income eligibility limit relative to the federal poverty level (most of the 11 funds above cap at 400–500% FPL) and require the patient to reapply on a renewal cycle, usually annually — our data carries the income limit percentage but not the specific renewal cadence for these funds, so confirm renewal timing on the foundation's own application.
A copay accumulator or maximizer is a health-plan feature that keeps manufacturer copay-card dollars from counting toward the patient's deductible or out-of-pocket max, so a patient can exhaust a program like CarePath's annual maximum and then owe the full coinsurance anyway once the plan stops crediting those payments. Whether a specific commercial plan runs an accumulator or maximizer is a plan-level detail our data does not carry; it is worth confirming with the patient's benefits before assuming the full CarePath benefit will apply toward their deductible.
Eligible commercial patients pay as little as $5 per infusion, up to $20,000 in program benefit per year, applied to copay, coinsurance or deductible.
No. CarePath's eligibility excludes Medicare, Medicaid, TRICARE, VA and other government coverage. Medicare patients depend on the foundation funds below, when one is open for their diagnosis.
Of the 11 foundation funds that list infliximab in our data, one — HealthWell Foundation's ANCA-associated vasculitis fund — is open today, but it requires its own confirmed diagnosis and doesn't help a Crohn's or ulcerative colitis patient. The Patient Advocate Foundation, PAN Foundation and HealthWell Foundation IBD-specific funds are all closed or waitlisted at our last check. A closed or waitlisted fund can reopen without notice as it receives new funding, which is why status has to be checked at the time of the infusion — CareCost re-checks closed funds and flags a reopening.
Yes. The Johnson & Johnson Patient Assistance Foundation provides Remicade free of charge to uninsured, income-eligible patients, with no annual benefit limit. It's a separate program from CarePath, which requires commercial insurance.
Sources: Janssen CarePath and Johnson & Johnson Patient Assistance Foundation program terms (jnjwithme.com, jjpaf.org); HealthWell Foundation, Patient Advocate Foundation, PAN Foundation and The Assistance Fund program pages; CareCost's programs bundle (public/programs-bundle.js), matched on HCPCS J1745 and generic name infliximab.